TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT06745713

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Student Information Form
Description: In the form developed by the researchers in line with the literature, a total of 12 questions were included to determine the socio-demographic characteristics of the students (such as age, gender, academic average, whether they provide care to patients with chest tubes, whether they receive training on chest tube care). All participants in the experimental and control groups were applied once as a pre-test.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Clinical Reasoning Readiness Scale for Nursing Students
Description: It is a comprehensive assessment tool developed by Huang Huiman (2018) to determine the clinical reasoning readiness levels of nursing students in Taiwan (Ho et al., 2021; H.-M. Huang et al., 2018). 'Clinical Reasoning Readiness Scale for Nursing Students' consists of 4 sub-dimensions. These sub-dimensions are 'awareness of clinical clues' (4 items), 'verification of clinical problems' (4 items), 'action determination and implementation' (4 items) and 'evaluation and reflection' (4 items). Each sub-dimension contains four items to assess students' clinical reasoning readiness levels. The lowest score that can be obtained from the scale is 16 and the highest score is 80. Responses to the scale are evaluated on a 5-point Likert scale (5=strongly agree, 4=agree, 3=decided, 2=disagree, 1=strongly disagree). Cronbach's α ranged from 0.894 for the total and 0.78 to 0.89 for each sub-dimension. The corrected item-total correlation is between 0.627-0.728. Higher scores indicate higher levels
Study: NCT06295510

Intervention type: OTHER
Intervention: No interventions.
Description: It's only observational study.

Intervention type: OTHER
Intervention: No interventions.
Description: It's only observational study.
Study: NCT04762069

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lomustine
Description: Lomustine is an anti-cancer (antineoplastic or cytotoxic) chemotherapy drug. This medication is classified as an alkylating agent.
Study: NCT06315387

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 4-MUST, 1 tablet
Description: 4-methylumbelliferyl trimebutine sulfate, 128 mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 4-MUST, 2 tablets
Description: 4-methylumbelliferyl trimebutine sulfate, 256 mg
Study: NCT06743607

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Immediate Intervention
Description: Participants will engage in a home exercise therapy program in combination with transcutaneous spinal stimulation intended to focus on the upper extremities that commences immediately after enrollment.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Waitlist control
Description: Participants will engage in a home exercise therapy program in combination with transcutaneous spinal stimulation intended to focus on the upper extremities that commences 12 weeks after enrollment.
Study: NCT06745024

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Best Practice
Description: Given SOC systemic anti-cancer therapy

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Best Practice
Description: Given SOC systemic anti-cancer therapy

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Patient Observation
Description: Undergo SOC observation

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Patient Observation
Description: Undergo SOC observation

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Bone Metastases Treatment
Description: Given bone modifying agent

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Bone Metastases Treatment
Description: Given bone modifying agent

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Biospecimen Collection
Description: Undergo blood sample collection

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biospecimen Collection
Description: Undergo blood sample collection

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Questionnaire Administration
Description: Ancillary studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies
Study: NCT06745505

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Bowel Preparation
Description: Group A received bowel preparation and Group B did not.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Bowel Preparation
Description: Group A received bowel preparation and Group B did not.
Study: NCT06744725

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Pleural biopsy using dual-function semirigid thoracoscopy
Description: Patients will receive pleural biopsy using dual-function semirigid thoracoscopy.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Pleural biopsy using semirigid thoracoscopy
Description: Patients received pleural biopsy using semirigid thoracoscopy
Study: NCT05844709

Intervention type: OTHER
Intervention: IVH care Bundle
Description: The experimental group received bundle nursing care within 3 days after birth in addition to routine nursing care after consent was given and the informed consent form was signed.~IVH care Bundle: 1. Maintaining midline head position 2. Avoid prone, place in supine or side-lying position 3. Incubator tilted 15-30 degrees 4. Slow withdrawal and flushing for UAC, UVC, and PAL.
Study: NCT05588557

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Marcaine® 100mg/20mL (0.5%) bupivacaine solution for Injection
Description: Subjects in this arm will receive a single administration of Marcaine® at the 150 mg.~Marcaine® will be administered under ultrasound guidance with a total volume of 40 mL, of which 20 mL will be used via adductor canal block (ACB) and the other 20 mL will be used as IPACK block (interspace between the popliteal artery and the capsule of the posterior knee).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ND-340 (Bupivacaine Microsphere), 300 mg/vial bupivacaine for extended-release injectable suspension
Description: Subjects in this arm will receive a single administration of ND-340 at the specified dose (90-320 mg).~ND-340 will be administered under ultrasound guidance with a total volume of 40 mL, of which 20 mL will be used via adductor canal block (ACB) and the other 20 mL will be used as IPACK block (interspace between the popliteal artery and the capsule of the posterior knee).
Study: NCT04451863

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Low THC
Description: Vaporized THC (5 mg)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Low THC
Description: Vaporized THC (5 mg)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Low THC
Description: Vaporized THC (5 mg)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Low THC
Description: Vaporized THC (5 mg)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Low THC
Description: Vaporized THC (5 mg)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: High THC
Description: Vaporized THC (15 mg)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: High THC
Description: Vaporized THC (15 mg)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: High THC
Description: Vaporized THC (15 mg)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: High THC
Description: Vaporized THC (15 mg)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: High THC
Description: Vaporized THC (15 mg)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: High THC
Description: Vaporized THC (15 mg)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Low Myrcene
Description: Vaporized Myrcene (0.5 mg)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Low Myrcene
Description: Vaporized Myrcene (0.5 mg)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Low Myrcene
Description: Vaporized Myrcene (0.5 mg)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: High Myrcene
Description: Vaporized Myrcene (12.0 mg)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: High Myrcene
Description: Vaporized Myrcene (12.0 mg)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: High Myrcene
Description: Vaporized Myrcene (12.0 mg)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Low Beta-Caryophyllene
Description: Vaporized Beta-Caryophyllene (0.5 mg)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Low Beta-Caryophyllene
Description: Vaporized Beta-Caryophyllene (0.5 mg)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Low Beta-Caryophyllene
Description: Vaporized Beta-Caryophyllene (0.5 mg)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: High Beta-Caryophyllene
Description: Vaporized Beta-Caryophyllene (7.5 mg)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: High Beta-Caryophyllene
Description: Vaporized Beta-Caryophyllene (7.5 mg)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: High Beta-Caryophyllene
Description: Vaporized Beta-Caryophyllene (7.5 mg)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Vaporized Placebo
Study: NCT05696080

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: V116
Description: Pneumococcal 21-valent conjugate vaccine with 4 μg of each of the following pneumococcal polysaccharides (PnPs) antigen: 3, 6A, 7F, 8, 9N, 10A, 11A, 12F, 15A, 15C, 16F, 17F, 19A, 20, 22F, 23A, 23B, 24F, 31, 33F, and 35B in each 0.5 mL sterile solution

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo for PCV15 + PPSV23
Description: Saline in each 0.5 mL sterile solution

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: PCV15
Description: Pneumococcal 15-valent conjugate vaccine with 2 μg of each of the following PnPs antigen: 1, 3, 4, 5, 6A, 7F, 9V, 14, 18C, 19A, 19F, 22F, 23F, and 33F; and 4 μg of PnPs antigen 6B in each 0.5 mL sterile suspension

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: PPSV23
Description: Pneumococcal 23-valent polyvalent vaccine with 25 μg of each of the following PnPs antigen: 1, 2, 3, 4, 5, 6B, 7F, 8, 9N, 9V, 10A, 11A, 12F, 14, 15B, 17F, 18C, 19A, 19F, 20, 22F, 23F, and 33F in each 0.5 mL sterile solution
Study: NCT05060523

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tolvaptan Tablets
Description: • Tolvaptan15 mg once a day for 7 days, stat with 7.5 mg and titrate to 15 mg in 24 hours max30 mg

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tolvaptan Tablets
Description: • Tolvaptan15 mg once a day for 7 days, stat with 7.5 mg and titrate to 15 mg in 24 hours max30 mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Midodrine Oral Tablet
Description: • Midodrine 5 mg at 0 hours and then 5 mg every 8 hours to maintain Target MAP-80

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: Placebo of Midodrine
Study: NCT05405127

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: traditional physical therapy
Description: breathing exercises 10 repetitions, 1set, 3 days/week and targeted abdominal muscles. Total 6 sessions were given each consisting of 30 minutes.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: core stability exercises
Description: core stability along with breathing exercise 10 repetitions, 1set, 3 days/week and targeted core muscles. Total 6 sessions were given consisting of 30 minutes.
Study: NCT05275660

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HFB30132A
Description: Participants randomized to HFB30132A will be administered dose 1 in cohort 1. Participants in Cohort 2 will receive HFB30132A dose 2.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Participants randomized to placebo will receive the same volume of solution as participants on active treatment.
Study: NCT06179433

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Root canal treatment
Description: Two-visit root canal treatment will be performed.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Regenerative endodontic procedure
Description: Regenerative endodontic procedure with i-PRF and blood clot induction will be performed.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Regenerative endodontic procedure
Description: Regenerative endodontic procedure with i-PRF and blood clot induction will be performed.
Study: NCT06782412

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: [18F]AlF-FAPI-74 PET/CT
Description: A \[18F\]AlF-FAPI-74 PET/CT will be performed at the same site of the screening visit (UZ Leuven, UZ Gent or UZ Antwerpen). Subjects are required to be sober four hours before the scan. The patient will get an IV line, through which the \[18F\]AlF-FAPI-74 will be injected in one bolus (3,5 MBq/kg). After 60 minutes, the acquisition on the PET/CT scan will take place. The CT will be a low dose CT with oral contrast. After the scan, participants will be observed at the department in case of adverse events. During this time, the participant can fill in the PRO. The estimated duration of this visit is three hours. If the patient receives neo-adjuvant therapy, a second \[18F\]AlF-FAPI-74 PET/CT will be performed maximum one month before surgery. If the planned surgery gets postponed after the second \[18F\]AlF-FAPI-74 PET/CT has been performed, we will have the possibility to perform one additional (i.e. third) \[18F\]AlF-FAPI-74 PET/CT, before the final surgery.

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: [18F]AlF-FAPI-74 PET/CT
Description: A \[18F\]AlF-FAPI-74 PET/CT will be performed at the same site of the screening visit (UZ Leuven, UZ Gent or UZ Antwerpen). Subjects are required to be sober four hours before the scan. The patient will get an IV line, through which the \[18F\]AlF-FAPI-74 will be injected in one bolus (3,5 MBq/kg). After 60 minutes, the acquisition on the PET/CT scan will take place. The CT will be a low dose CT with oral contrast. After the scan, participants will be observed at the department in case of adverse events. During this time, the participant can fill in the PRO. The estimated duration of this visit is three hours. If the patient receives neo-adjuvant therapy, a second \[18F\]AlF-FAPI-74 PET/CT will be performed maximum one month before surgery. If the planned surgery gets postponed after the second \[18F\]AlF-FAPI-74 PET/CT has been performed, we will have the possibility to perform one additional (i.e. third) \[18F\]AlF-FAPI-74 PET/CT, before the final surgery.
Study: NCT06770010

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cogmed+
Description: Cogmed is a home-based, digital working memory training program compatible with tablet devices. The program, designed for children ages 7 and older, consists of engaging cognitive exercises that target skills involving visuospatial and verbal working memory. An essential component of Cogmed training involves assignment of an intervention coach who has access to detailed data on the user's training data. Families will have videoconference meetings once per week with an intervention coach to review progress, provide feedback and answer any questions that arise during treatment. In addition, participants' coaching calls will be supplemented with direct instruction on the use of memory strategies. Social support interventions will also be provided involving three primary approaches: (1) multi-family Cogmed Kickoff social events; (2) social incentives; and (3) peer navigator support.
Study: NCT06781775

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Metformin + Insulin
Description: Pregnant women who have have gestational diabetes and have uncontrolled blood sugar with metformin alone will stay on metformin and add insulin.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Insulin
Description: Pregnant women who have have gestational diabetes and have uncontrolled blood sugar with metformin alone will stop on metformin and add insulin.
Study: NCT06780670

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Investigators choice of SoC
Description: The control treatment in Phase III is investigator's choice of SoC

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AAA817
Description: The investigational treatment is AAA817
Study: NCT06315387

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 4-MUST, 3 tablets
Description: 4-methylumbelliferyl trimebutine sulfate, 384 mg
Study: NCT06780670

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AAA817
Description: The investigational treatment is AAA817

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AAA817
Description: Investigational treatment is the Dose B of AAA817
Study: NCT06780007

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Probiotic
Description: The trial phase of the study will last 12 weeks and each subject will make 4 follow-up visits (day 0, week 4, week 8 and week 12).

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: The trial phase of the study will last 12 weeks and each subject will make 4 follow-up visits (day 0, week 4, week 8 and week 12).
Study: NCT06781385

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intra-arterial Tenecteplase
Description: One-time dose of intra-arterial tenecteplase post-thrombectomy

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Intra-arterial Saline
Description: One-time dose of intra-arterial saline post-thrombectomy
Study: NCT04969393

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: High intensity laser therapy
Description: Fifteen treatment sessions with pulsed Nd: YAG laser were applied to the subjects of the study group, three sessions per week, over 5 weeks in succession via EXAND MY 1064 nm Laser system, Mectronic Medicale, Italy. Patients in group (A) received HILT along with the conventional physical therapy program. The session involved 3 subphases: (1) The Initial phase Analgesic phase, (2) In the intermediate phase Trigger point phaseand (3)The final phase Bio-stimulation phase was applied for 6 minutes with a slow scanning in several parallel longitudinal lines.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Conventional Physical Therapy
Description: Fifteen treatment sessions that involved using a neutral custom volar splint alongside neural and tendon gliding exercises. the splint was used at night and while performing strenuous activities during the day for 5 weeks. While nerve and tendon gliding exercises was repeated 10 times at each session and patients were encouraged to apply exercise 3-5 times per day for 5 weeks.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Conventional Physical Therapy
Description: Fifteen treatment sessions that involved using a neutral custom volar splint alongside neural and tendon gliding exercises. the splint was used at night and while performing strenuous activities during the day for 5 weeks. While nerve and tendon gliding exercises was repeated 10 times at each session and patients were encouraged to apply exercise 3-5 times per day for 5 weeks.
Study: NCT05894018

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluzoparib
Description: 150mg, orally, bid
Study: NCT05702762

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Gentamicin
Description: 5 mg/kg intramuscular injection

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Standard of Care
Description: Usual oral antibiotic multi-day dosing based on local antibiogram
Study: NCT05848908

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Telehealth Visit
Description: telemedicine visit and follow-up surveys
Study: NCT06065839

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: non-nutritive sucking 5 minutes
Description: Give pacifier non-nutritive sucking for 5 minutes before feeding

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: non-nutritive sucking 15 minutes
Description: Give pacifier non-nutritive sucking for 15 minutes before feeding
Study: NCT06782399

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Microdevice
Description: Device: Microdevices~The microdevice is an investigational miniaturized implantable nanodose drug delivery device. It was developed as a tool with the ultimate goal to help screen several existing and investigational drugs directly within a patient's tumor to identify what drugs are the most effective for treating a patient's cancer. The microdevice releases nanodoses of several approved drugs into the tumor, and is then excised minimally invasively several days later.~Other: Standard of care therapy~Participant to receive standard of care therapy as previously determined by participant's treating oncologist and/or dermatologist, which may include a skin-directed or systemic therapy
Study: NCT05064917

Intervention type: DIAGNOSTIC_TEST
Intervention: Blood draw
Description: The burden for child/parents in this study is low as it is limited to a single blood draw, which is already necessary for usual diagnostic care in about 70% of the children
Study: NCT06040606

Intervention type: PROCEDURE
Intervention: In-Hospital COVID-19 Omicron Infection after surgery
Description: Thoracic Surgery Patients with In-Hospital COVID-19 Omicron Infection after surgery
Study: NCT05894018

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Radioactive particle implantation
Description: Radioactive iodine-125 seeds implantation
Study: NCT04790006

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TG103
Description: Administered SC
Study: NCT06780371

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Emotional Freedom Technique
Description: Emotional Freedom Technique application; It is an application that works on cognitive and energetic levels.~Emotional Freedom Technique Application Instructions~1. Determination of Subjective Units of Disturbance (SUD)~2. Preparation or setup~3. Application of appropriate acupuncture points in order~4. 9-Gamut: An application that allows the two hemispheres of the brain to be stimulated simultaneously~5. Application of appropriate acupuncture points in order again~6. Control of the differentiation in the level of discomfort with SUDS again
Study: NCT04790006

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Administered SC
Study: NCT06780228

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: chatbot-assisted clinical learning
Description: The participants will recevie a self-developed web-based chatbot platform which is accessible via smartphones. It provides real-time dialogue with the chatbot through texts, visual aids, and audio files. The intervention will be available throughout the 12-week study. the chatbot is characterized by a gender-neutral persona, assumes the role of a friendly and empathetic clinical mentor. Its communication style can be described as calm, tolerant, supportive, and appreciative. Participants will receive weekly SMS notifications to remind them to consult with the chatbot.